Ο Στέφανος Οικονόμου στην εκπομπή της ΕΡΤ "Από τις έξι"
ΟΙΚΟΝΟΜΟΥ ΦΑΝΗ
ΟΙΚΟΝΟΜΟΥ ΠΑΝΑΓΙΩΤΗΣ
ΟΙΚΟΝΟΜΟΥ ΦΑΝΗ
ΟΙΚΟΝΟΜΟΥ ΠΑΝΑΓΙΩΤΗΣ

EXTENSION OF CAPABILITY TO OFFSET CLAWBACK

During the latest amendment of Article 11 of Law 4052/2012, paragraph g was added to the Article, which specifies that the total amount of clawback for an EOPYY pharmaceutical expense and the hospital pharmaceutical expenditure paid by Marketing Authorisation Holders of pharmaceutical products or pharmaceutical companies may be offset, pursuant to the provisions of Articles 22A and 23 of Law 4172/2013 (167/A), against the amount that corresponds to: i. the percentage over the research and development expenses, including the expenses for clinical trials, which are directly linked to research and development activities of a specific scope and nature, ii. the percentage over the expenses that correspond to investment plans for development of products, services or production lines.

This option strengthens Greek research and production, and by extension the Greek pharmaceutical industry, and is undoubtedly a positive development.

With its vast experience in pharmaceutical law, commercial law and compliance, the Stefanos Economou & Associates Law Firm is able to meet all the needs of pharmaceutical companies, pharmaceutical warehouses and medical equipment companies for legal services, either as an advisor or before the courts and authorities.